– Efficacy benefits with recently approved combination regimen observed regardless of baseline International Metastatic Renal Cell Carcinoma Database Consortium risk status, organ site of metastases or extent of tumor burden
– Data to be presented during the 2021 American Society of Clinical Oncology’s Annual Meeting –